TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16945213

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0
Study: 14578226

Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (Ae+RT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aerobic only training (Ae only)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 10749783

Group type: EXPERIMENTAL
Intervention: Endotoxin (lowest dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endotoxin (highest dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8703455

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Obstructive sleep apnea syndrome
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gastric bypass procedure
Number of subjects: 14
Study: 1305043

Group type: EXPERIMENTAL
Intervention: Ukrain (2.5 to 25 mg per injection, intramuscularly or intravenously, every 1-5 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ukrain (various dosing schedules and intervals)
Number of subjects: 70
Study: 3977491

Group type: EXPERIMENTAL
Intervention: 3 micrograms of heat-inactivated hepatitis B vaccine
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 27 micrograms of heat-inactivated hepatitis B vaccine
Number of subjects: 227
Study: 29884682

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation
Number of subjects: 420

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 420
Study: 26708675

Group type: EXPERIMENTAL
Intervention: Cooling plus 30% inhaled xenon for 24 h started immediately after randomisation.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cooling to a rectal temperature of 33·5°C for 72 h (standard treatment).
Number of subjects: 92
Study: 24866594

Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-sleep condition
Number of subjects: 40
Study: 23197572

Group type: EXPERIMENTAL
Intervention: Tadalafil (a phosphodiesterase 5A inhibitor), single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21542450

Group type: EXPERIMENTAL
Intervention: Self-help workbook
Number of subjects: 49

Group type: COMPARATOR
Intervention: Information booklet (control)
Number of subjects: 49
Study: 18091705

Group type: EXPERIMENTAL
Intervention: Interstitial magnetic resonance lymphography (MRL) using subcutaneous gadobutrol (5 mL: 4.5 mL Gadobutrol + 0.5 mL lidocaine hydrochloride)
Number of subjects: 6

Group type: COMPARATOR
Intervention: X-ray direct lymphography (lipiodol administered after 7 days in 3 patients)
Number of subjects: 6
Study: 16298064

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: First-degree relatives of children with headache
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (children without primary headache)
Number of subjects: 130
Study: 12077007

Group type: EXPERIMENTAL
Intervention: British Sign Language (BSL) processing in congenitally deaf native users
Number of subjects: 18

Group type: COMPARATOR
Intervention: Audio-visual English processing in hearing non-signers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison of BSL and audio-visual English
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BSL in deaf signers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Audio-visual English in hearing subjects
Number of subjects: 18
Study: 9462315

Group type: EXPERIMENTAL
Intervention: Community multidisciplinary teams
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hospital based care programmes
Number of subjects: 155
Study: 7630032

Group type: EXPERIMENTAL
Intervention: Smoking cessation education program at branch A
Number of subjects: 2

Group type: COMPARATOR
Intervention: No smoking cessation education at branch B
Number of subjects: 2
Study: 2799034

Group type: EXPERIMENTAL
Intervention: Creon (7 capsules, 2.1 g pancreatin, 70,000 UFIP lipase)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pankreon 700 (17 tablets, 11.9 g pancreatin, 476,000 UFIP lipase)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (first week without treatment)
Number of subjects: 12
Study: 31609974

Group type: EXPERIMENTAL
Intervention: Mentor Mother (MM) programme
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Standard PMTCT services without MM intervention
Number of subjects: 2304
Study: 29178761

Group type: EXPERIMENTAL
Intervention: FP/ProRoot mineral trioxide aggregate (MTA)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: FP/calcium enriched mixture (CEM)
Number of subjects: 412
Study: 25580606

Group type: EXPERIMENTAL
Intervention: Dual-channel portable monitor (PM)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dual-channel portable monitor (PM) in simultaneous laboratory comparison
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Manual PM data review
Number of subjects: 104
Study: 23427838

Group type: EXPERIMENTAL
Intervention: Hypnotic tape intervention (audio recording of a hypnotic induction with suggestions for progressive relaxation, imagery, and anchoring) used for 2 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hypnotic tape intervention
Number of subjects: 35
Study: 21358373

Group type: EXPERIMENTAL
Intervention: Nurse-coached telephone intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 102
Study: 19082662

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication without division of short gastric vessels (group 1, n = 19)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nissen fundoplication with division of short gastric vessels (group 2, n = 22)
Number of subjects: 41
Study: 16395320

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 65
Study: 15054404

Group type: EXPERIMENTAL
Intervention: 35 mg/d isoflavone supplement for 3 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonsupplemented diets
Number of subjects: 15
Study: 10828806

Group type: EXPERIMENTAL
Intervention: 24 hours of nasal packing
Number of subjects: 104

Group type: COMPARATOR
Intervention: 48 hours of nasal packing
Number of subjects: 104
Study: 9104618

Group type: EXPERIMENTAL
Intervention: Endonasal administration of an IgA enriched preparation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8478668

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg/d
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/d
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 1280 mg/d
Number of subjects: 342
Study: 3532099

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 21

Group type: COMPARATOR
Intervention: pirlindol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 21
Study: 31580044

Group type: EXPERIMENTAL
Intervention: Energy device (group C)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Synthetic glue (group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard procedure (group A)
Number of subjects: 71
Study: 30056414

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 30
Study: 26272330

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg QD × 5 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg QD × 5 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Alcohol (40-g single dose)
Number of subjects: 34
Study: 24763156

Group type: EXPERIMENTAL
Intervention: Yoga therapy intervention (6-week program, twice weekly group classes and once weekly home practice)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Yoga therapy intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study: 22667695

Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Traditional group
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study: 20185596

Group type: EXPERIMENTAL
Intervention: Octreotide (40 mg every 28 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12
Study: 19022134

Group type: COMPARATOR
Intervention: Closed reduction and mandibulomaxillary fixation (CRMMF)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 66
Study: 15750149

Group type: EXPERIMENTAL
Intervention: Probe A (scintillator with bismuth germanate crystal)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Probe B (semiconductor with cadmium telluride crystal)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Probe C (semiconductor with cadmium zinc telluride crystal)
Number of subjects: 200

Group type: COMPARATOR
Intervention: All probes
Number of subjects: 200
Study: 12198052

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of propofol (plasma target concentration, 2.5-3.5 micro g/mL; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manually-Controlled Infusion (MCI) of propofol (3.0-4.0 mg.kg(‐1).h(‐1); n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time to extubation (TCI: 13.7 +/- 5.3 min; MCI: 12.3 +/- 3.5 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Costs of anesthesia (TCI: 39.73 US dollars; MCI: 34.83 US dollars)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BIS measurements at various time points (T1 to T6)
Number of subjects: 40
Study: 10670292

Group type: EXPERIMENTAL
Intervention: Pegasus Trinova (dynamic integrated mattress and seat cushion system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory measures of interface pressure
Number of subjects: 0
Study: 7489931

Group type: EXPERIMENTAL
Intervention: Triple therapy + omeprazole (20 mg twice daily)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Triple therapy + famotidine (40 mg at night)
Number of subjects: 336
Study: 2031196

Group type: EXPERIMENTAL
Intervention: Lonidamine, 350 mg/m2 orally daily (arm A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High dose tamoxifen, 150 mg/m2 orally daily for 6 months, then 50 mg/m2 until tumor progression (arm B)
Number of subjects: 60
Study: 16435471

Group type: EXPERIMENTAL
Intervention: ranitidine (320 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cimetidine (800 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 40
Study: 31022886

Group type: EXPERIMENTAL
Intervention: Organizational intervention targeting work organization and environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 0
Study: 28167545

Group type: COMPARATOR
Intervention: MRX-I single ascending doses under fasting or fed condition
Number of subjects: 66

Group type: COMPARATOR
Intervention: MRX-I 800 mg every 12 hours for 14 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MRX-I 800 mg every 12 hours for 28 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Linezolid 600 mg every 12 hours for 28 days
Number of subjects: 66
Study: 25294016

Group type: EXPERIMENTAL
Intervention: Siltuximab (6 mg/kg IV every 2 weeks) + Bortezomib (B)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo + Bortezomib (B)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Siltuximab + Bortezomib
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo + Bortezomib
Number of subjects: 281
Study: 23590362

Group type: EXPERIMENTAL
Intervention: Hyperthermia group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21255957

Group type: EXPERIMENTAL
Intervention: RVX-208 (50, 100, or 150 mg twice daily for 12 weeks)
Number of subjects: 299
Study: 19593886

Group type: EXPERIMENTAL
Intervention: Scheduled analgesia with lornoxicam (8 mg preoperatively, 8 mg after 6-8 hours, and 8 mg every 8 hours for 48 hours postoperatively)
Number of subjects: 126

Group type: COMPARATOR
Intervention: On request analgesia with lornoxicam (as needed)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Infratentorial craniotomy patients in group 1
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 126
Study: 16512935

Group type: COMPARATOR
Intervention: 0 g F&V per day (Control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 300 g F&V per day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 600 g F&V per day
Number of subjects: 62
Study: 15296886

Group type: EXPERIMENTAL
Intervention: Leucodepletion using an arterial line leucocyte-depleting filter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard filter (Control)
Number of subjects: 50
Study: 11385269

Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg rapidly disintegrating tablet
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: rizatriptan 10-mg
Number of subjects: 481

Group type: COMPARATOR
Intervention: sumatriptan 50-mg tablet
Number of subjects: 481
Study: 9285433

Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 24
Study: 8418302

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2874783

Group type: EXPERIMENTAL
Intervention: Epinephrine added to betaxolol treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Epinephrine added to timolol treatment
Number of subjects: 19
Study: 29853453

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), an IL-6 receptor-α inhibitor, administered for 24 weeks.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo, administered for 24 weeks.
Number of subjects: 12
Study: 26711799

Group type: EXPERIMENTAL
Intervention: High-rate cutoff with VT therapy ≥200 (Treatment arm B)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Prolonged 60-second delay for VT therapy ≥170 (Treatment arm C)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Conventional with VT therapy ≥170 (Treatment arm A)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Any ICD programming
Number of subjects: 1500
Study: 25330017

Group type: EXPERIMENTAL
Intervention: Buprenorphine taper
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ongoing buprenorphine maintenance therapy
Number of subjects: 113
Study: 23735180

Group type: EXPERIMENTAL
Intervention: Test sirolimus tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference sirolimus tablets
Number of subjects: 24
Study: 20619475

Group type: EXPERIMENTAL
Intervention: 360 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Number of subjects: 896

Group type: COMPARATOR
Intervention: 180 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Number of subjects: 896
Study: 18226255

Group type: EXPERIMENTAL
Intervention: Nurse-based intervention supporting self-management of OA symptoms
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 104
Study: 15679790

Group type: EXPERIMENTAL
Intervention: Safyre sling procedure
Number of subjects: 126
Study: 12817361

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 680
Study: 10876066

Group type: EXPERIMENTAL
Intervention: Meditation (TM-Sidhi or yoga)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control night (no meditation)
Number of subjects: 0
Study: 8852414

Group type: EXPERIMENTAL
Intervention: Oral B subunit‐killed whole cell (BS‐WC) vaccine
Number of subjects: 62285

Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) vaccine
Number of subjects: 62285

Group type: COMPARATOR
Intervention: K12 group (control)
Number of subjects: 62285
Study: 1737542

Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin infusion (IP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subcutaneous intensive insulin therapy (SC)
Number of subjects: 21
Study: 6151483

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 31575423

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure control targeting <120 mm Hg
Number of subjects: 8151

Group type: COMPARATOR
Intervention: Systolic blood pressure control targeting 135 to 139 mm Hg
Number of subjects: 8151

Group type: EXPERIMENTAL
Intervention: <10% 10‐year risk
Number of subjects: 8151

Group type: EXPERIMENTAL
Intervention: ≥30% 10‐year risk
Number of subjects: 8151

Group type: EXPERIMENTAL
Intervention: Primary prevention (≥30% risk)
Number of subjects: 8151

Group type: EXPERIMENTAL
Intervention: Secondary prevention (≥30% risk)
Number of subjects: 8151
Study: 29045659

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (BEV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 102
Study: 26914135

Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin per os (Group P75)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin per os (Group P150)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin per os (Group P300)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (Group C)
Number of subjects: 80
Study: 24552826

Group type: EXPERIMENTAL
Intervention: Anabolic steroids combined with a daily high-protein, high-calorie diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (high-protein, high-calorie diet alone)
Number of subjects: 32
Study: 22142813

Group type: EXPERIMENTAL
Intervention: Griffonia Simplicifolia extract (5-hydroxytryptophan) administered via oral spray for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks
Number of subjects: 20
Study: 19281581

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 160

Group type: COMPARATOR
Intervention: 50 mg pethidine
Number of subjects: 160
Study: 17192712

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-demented elderly control sample (n = 183)
Number of subjects: 45
Study: 15776183

Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg orally, administered 60 to 30 minutes before anesthesia)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (administered 60 to 30 minutes before anesthesia)
Number of subjects: 178
Study: 12194123

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 25
Study: 10581593

Group type: EXPERIMENTAL
Intervention: Combined protocol (oral acipimox + insulin clamp)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin clamp alone (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard protocol (insulin clamp)
Number of subjects: 20
Study: 8074597

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium, 60 mg, over 4 hours
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium, 60 mg, over 24 hours
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 69
Study: 2912119

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% balanced salt solution (placebo)
Number of subjects: 60
Study: 31613029

Group type: EXPERIMENTAL
Intervention: Low-intensity blood flow restricted (BFR) training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-intensity interval training without BFR (LOW)
Number of subjects: 24
Study: 28583396

Group type: EXPERIMENTAL
Intervention: CompEx (composite outcome based on diary events and severe exacerbations)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Severe exacerbations
Number of subjects: 12
Study: 26522337

Group type: EXPERIMENTAL
Intervention: Nedaplatin plus docetaxel (100 mg/m² nedaplatin and 60 mg/m² docetaxel every 3 weeks for four to six cycles)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Cisplatin plus docetaxel (80 mg/m² cisplatin and 60 mg/m² docetaxel every 3 weeks for four to six cycles)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Nedaplatin
Number of subjects: 355

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 355
Study: 23413998

Group type: EXPERIMENTAL
Intervention: Fluoxetine co-administration with clopidogrel
Number of subjects: 8
Study: 22091692

Group type: EXPERIMENTAL
Intervention: Multimodal comprehensive discharge‐planning intervention
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 665
Study: 19589442

Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Bare‐metal stents (BMS)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Sirolimus‐eluting stents (SES)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stents (PES)
Number of subjects: 649
Study: 16675081

Group type: EXPERIMENTAL
Intervention: Decline eccentric squats
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard eccentric squats
Number of subjects: 13
Study: 15182397

Group type: EXPERIMENTAL
Intervention: Phenolic-rich dessert (200 g daily for 2 weeks)
Number of subjects: 22
Study: 11986104

Group type: EXPERIMENTAL
Intervention: Artisan lens implantation
Number of subjects: 90

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 90
Study: 9848833

Group type: EXPERIMENTAL
Intervention: Topical anesthetic (one drop before lens insertion at fitting and dispensing visits)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8123500

Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: D‐tryptophan‐6‐LHRH (Control)
Number of subjects: 24